Impact of hypoglycemic medication on the cardiovascular risk in patients with type 2 diabetes
M.G. EVSINA1, E.M. VISHNEVA2, E.M. FUTERMAN2, S.E. ESEVA2
1Municipal Clinical Hospital №14, 15A 22 Partsyezda Str., Ekaterinburg, Russian Federation, 620039
2Ural State Medical University, 3 Repin Str., Ekaterinburg, Russian Federation, 620028
Evsina M.G. ― doctor of functional diagnostics, tel. +7-908-631-39-08, e-mail: evsinam@mail.ru
Vishneva E.M. ― D. Med. Sc., Associate Professor of the Department of Faculty Therapy and Diagnostics, tel. +7-912-241-86-52, e-mail: e.m.vishneva@mail.ru
Futerman E.M. ― Cand. Med. Sc., Assistant of the Department of Faculty Therapy and Diagnostics, tel. +7-912-030-42-16, e-mail: efuterman@mail.ru
Eseva S.E. ― 6th year student, тел. +7-912-030-42-16, e-mail: efuterman@mail.ru
Type 2 diabetes mellitus is a steadily extending disease, which is associated with the increased risk of cardiovascular events. The article reviews the modern hypoglycemic agents and assesses their influence on cardiovascular risk factors and development of cardiovascular diseases taking into account the results of modern clinical and pilot studies.
Key words: type 2 diabetes mellitus, antidiabetic drugs, cardiovascular risk, treatment.
REFERENCES
- Morozova T.E., Andrushchishina T.B. Cardiovascular therapy and prophylaxis in diabetic patients. Lechashchiy vrach, 2009, no. 7, pp. 29-32 (in Russ.).
- Dedov I.I., Shestakova M.V., Aleksandrov A.A. et al. Algorithms of specialized medical care for patients with diabetes mellitus. Sakharnyy diabet, 2013, no. 1 (in Russ.).
- World Heart Federation. Cardiovascular Disease Risk Factors: Diabetes. Geneva, Switzer-land: World Heart Federation; 2014.
- American Diabetes Association Standards of Medical Care in Diabetes. Diabetes Care, 2014, no. 36, rr. 14-87.
- Terekhova A.L., Zilov A.V. The main causes of death and concomitant pathology in patients with type 2 diabetes by autopsy results. Sakharnyy diabet, 2011, no. 4, pp. 61-64 (in Russ.).
- Aquilante C.L. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev. Cardiovasc. Ther, 2010, no. 8, rr. 359-372.
- Schramm T.K., Gislason G.H., et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J, 2011, no. 15, rr. 1900-1908.
- Hemmingsen B., Schroll J.B., Lund S.S., et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst. Rev, 2013, no. 4, CD009008.
- Roumie C.L., Liu X., Choma N.N., et al. Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year. Pharmacoepidemiol Drug Saf, 2012, no. 21, rr. 515-523.
- Abdelmoneim A.S. et al. Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction. Int. J. Cardiol, 2015, no. 9, rr. 126-130.
- Seino S. and Miki T. KATP channels as metabolitic sensors: protective roles against acute metabolic changes. Medicographia, 2005, no. 4, rr. 307-310.
- Tanabe M., Nomiyama T., Motonaga R., et al. Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database. BMC Endocrine Disorders, 2015, no. 15, r. 49.
- Yanping Li, Yang Hu, Sylvia H. Ley, et al. Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women. Diabetes Care, 2014, no. 11, rr. 3106-3113.
- Tan F., Li H., Ma M., et al. Protective effect of treatment with low-dose gliclazide in a model of middle cerebral artery occlusion and reperfusion in rats. Brain Res, 2014, no. 4, rr. 83-90.
- Caffes N., Kurland D.B., Gerzanich V., et al. Glibenclamide for the treatment of ischemic and hemorrhagic stroke. Int. J. Mol. Sci, 2015, no. 3, rr. 4973-4984.
- Chen D.M., Yu Y.R. Effects of sulfonylureas on patients with type 2 diabetes and acute nonlacunar ischemic stroke. Sichuan Da Xue Xue Bao Yi Xue Ban, 2014, no. 5,rr. 810-813.
- Stephanie Aleskow Stein, Elizabeth Mary Lamos, Stephen N. Davis. A review of the efficacy and safety of oral antidiabetic drugs. Expert. Opin. Drug. Saf, 2013, no. 2, rr. 153-175.
- Nakashima E. Prandial glucose regulator and insulin secretagogue; glinide and its combination therapy. Nihon Rinsho, 2015, no. 3, rr. 416-423.
- Monami M., Genovese S., Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab, 2013, no. 15, rr. 938-953.
- Huang Y., Abdelmoneim A.S., Light P., et al. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J. Diabetes Complications, 2015, no. 2, rr. 196-202.
- World Health Organization. WHO Model List of Essential Medicines. Geneva: World Health Organization, 2013.
- Logie L., Harthill J., Patel K., et al. Cellular responses to the metal-binding properties of metformin. Diabetes, 2012, no. 61, rr. 1423-1433.
- Repiscak P., Erhardt S., Rena G., et al. Biomolecular mode of action of metformin in relation to its copper binding properties. Biochemistry, 2014, no. 53, R. 787-795.
- Druk I.V. Metformin in the treatment of type 2 diabetes: a bestseller that has not been read to the end. Lechashchiy vrach, 2011, no. 5, pp. 79-84 (in Russ.).
- Fung C.S., Wan E.Y., Wong C.K., et al. Effect of metformin monotherapy on cardiovas-cular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients. Cardiovasc Diabetol, 2015, no. 1, rr. 137.
- Kooy A., de Jager J., Lehert P., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med, 2009, no. 169, rr. 616-625.
- Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med, 2008, no. 359, rr. 1577-1589.
- Chang C.H., Chang Y.C., Lin J.W., et al. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study. J. Clin. Endocrinol. Metab, 2015, no. 33, rr. 1121-1129.
- Aleksandrov A.A. Thiazolidinediones — agonists of gamma-receptors activated by peroxisome proliferators: «What’s in a name for you?». Russkiy meditsinskiy zhurnal, 2011, vol. 19, no. 13, pp. 847-852 (in Russ.).
- Tzoulaki I., Molokha M., Curcin V., et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ, 2009, no. 339, b4731.
- Roussel R. et al. Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality. Int. J. Cardiol, 2013, no. 4, rr. 1380-1384.
- Lu C.J., Sun Y., Muo C.H., et al. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovasc Dis, 2013, no. 2, rr. 145-151.
- James J. DiNicolantonio, Jaikrit Bhutani and James H. O’Keefe. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart, 2015, no. 1, e000327.
- Peng X., Zhang G., Liao Y., et al. Inhibitory kinetics and mechanism of kaempferol on α-glucosidase. Food Chem, 2016, no. 190, rr. 207-215.
- O’keefe J.H., Gheewala N.M., O’keefe J.O. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J. Am. Coll. Cardiol, 2008, no. 51, rr. 249-255.
- Shimabukuro M., Higa M., Yamakawa K., et al. Miglitol, α-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study. Int. J. Cardiol, 2013, no. 5, rr. 108-113.
- Yamasaki Y. et al. Alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res. Clin. Pract, 2005, no. 3, rr. 204-210.
- Chen J.M., Chang C.W., Lin Y.C., et al. Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study. J. Diabetes Res, 2014, no. 8, rr. 126-128.
- Ametov A.S. Regulation of insulin secretion in norm and in type 2 diabetes mellitus: the role of incretins. Russkiy Meditsinskiy Zhurnal, 2006, vol. 14, no. 26, pp. 1867-1872 (in Russ.).
- Holst J.J., Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am. J. Physiol. Endocrinol. Metab, 2004, no. 287, R. 199-206.
- Antsiferov M.B., Dorofeeva L.G. New approaches in the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 and exenatide (Baeta). Farmateka, 2007, no. 11, pp. 14-19 (in Russ.).
- Takei I., Kasatani T. Future therapy of diabetes mellitus. Biomed Pharmacother, 2004, no. 58, rr. 578-581.
- Nauck M.A. Glucagon – like peptide 1 (GLP-1) in the treatment of diabetes. Horm. Metab. Res, 2004, no. 36, rr. 852-858.
- Antsiferov M.B., Koteshkova O.M. Experience in the use of incretinomimetics exenatide (Baeta) in the treatment of patients with type 2 diabetes with obesity. Farmateka, 2009, no. 3, pp. 32-37 (in Russ.).
- DeFronzo R.A., Okerson T., Viswanathan P., et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin, 2008, no. 10, rr. 2943-2952.
- Lee T.I., Kao Y.H., Chen Y.C., et al. The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes. Int. J. Cardiol, 2013, no. 168, rr. 5390-5395.
- Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet, 2007, no. 370, rr. 1129-1136.
- Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 2009, no. 374, rr. 39-47.
- Rosenstock J., Baron M.A., Dejager S., et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care, 2007, no. 30, rr. 217-223.
- Okerson T., Yan P., Stonehouse A., et al. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am. J. Hypertens, 2010, no. 23, rr. 334-339.
- Nystrom T., Gutniak M.K., Zhang Q., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab, 2004, no. 287, rr. 1209-1215.
- Arakawa M., Mita T., Azuma K., et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes, 2010, no. 59, rr. 1030-1037.
- Ban K. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and independent pathways. Circulation, 2008, no. 117, rr. 2340-2350.
- Darsalia V., Ortsäter H., et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes, 2013, no. 4, rr. 1289-1296
- Adamíková A. Possibilities of therapy GLP1 RA for diabetics with nephropathy. Vnitr Lek, 2015, no. 4, rr. 312-315.
- Green J.B. et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med, 2015, no. 3, rr. 232-242.
- Chen D.Y. et al. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study. Int. J. Cardiol, 2015, no. 181, rr. 2006.
- Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med, 2013, no. 369, rr. 1317-1326.
- Udell J.A. at al. SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, no. 38, rr. 696-705.
- Rosenstock J., Marx N., Neubacher D., et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol, 2015, no. 14, r. 57.
- Maeda S., Yamagishi S., Matsui T., et al. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats. Ophthalmic Res, 2013, no. 50, rr. 221-226.
- McInnes G., Evans M., Del Prato S., et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17,000 patients. Diabetes Obes. Metab, 2015, no. 11, rr. 1085-1092.
- Nauck M.A., Del Prato S., Meier J.J., et al. Dapagliflozin versus glipizide as add- on therapy in patients with type 2 diabetes who have inadequete glyceamic control with metformin: a randomised, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care, 2011, vol. 34, pp. 2015-2022.
- Basile J.N. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J. Diabetes Complications, 2013, 27 (3), pp. 280–286
- U.S. Food and Drug Administratio, available at: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm